Three Cases of Herpes Zoster Radiculitis in MS Patients Treated with Natalizumab

Abstract Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been ra...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2016-09, Vol.9, p.122-124
Main Authors: Yamout, Bassem I, Zeid, Nuhad Abou, Taha, Ali J, Zeineddine, Maya M, Khoury, Samia J
Format: Article
Language:English
Subjects:
Female
Herpes zoster
Herpes Zoster - complications
Humans
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Lebanon
Middle Aged
Middle East
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - complications
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Natalizumab
Natalizumab - adverse effects
Natalizumab - therapeutic use
Neurology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2016.07.012